{"id":"W2031191883","doi":"10.1158/1538-7445.am2013-lb-67","title":"Abstract LB-67: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Ramucirumab; Medicine; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Gastroenterology; Cancer; Progression-free survival; Bevacizumab; Oncology; Randomized controlled trial; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009164907,0.0002565806,0.0008492118,0.0005556403,0.0001467809,0.0000573047,0.0001199754,0.00005313968,0.0002203152],"category_scores_gemma":[0.0002242366,0.000146113,0.0002043502,0.0005373007,0.0002891071,0.0001513601,0.00005167141,0.0002575057,0.000002596453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003863496,"about_ca_system_score_gemma":0.0003430138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001724663,"about_ca_topic_score_gemma":0.0003912266,"domain_scores_codex":[0.9972654,0.0002438267,0.0006113747,0.0004467957,0.0009686403,0.0004639682],"domain_scores_gemma":[0.9980937,0.0008926627,0.000226912,0.0003571785,0.0001967817,0.0002328286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9592904,0.001311459,0.003093684,0.0004847321,0.0003576004,0.000248371,0.002220225,0.00002058852,0.00003552075,0.000008060667,0.0002298991,0.03269944],"study_design_scores_gemma":[0.9778618,0.01242597,0.003586045,0.0004666506,0.0008513555,0.000003770602,0.004094982,0.0001224592,0.0003673326,0.00001333944,0.0001064183,0.00009982842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849948,0.003771162,0.000012241,0.0007142524,0.0002106914,0.01008889,0.00002555725,0.00001011825,0.0001723073],"genre_scores_gemma":[0.9949961,0.001635567,0.00006000588,0.00001172349,0.0001865193,0.002708796,0.00006663799,0.00002346836,0.0003111652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03259961,"threshold_uncertainty_score":0.5958316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1331793739946357,"score_gpt":0.4416337284529729,"score_spread":0.3084543544583372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}